icon-    folder.gif   Conference Reports for NATAP  
  IAS 2013: 7th IAS Conference on HIV
Pathogenesis Treatment and Prevention
June 30 - July 3 2013
Kuala Lumpur, Malaysia
Back grey_arrow_rt.gif
Dolutegravir (DTG) is Superior to Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: Week 48 Results From SAILING (ING111762)
  Reported by Jules Levin
IAS Kuala Lumpur June 30-July 3 2013
Pedro Cahn,1 Anton Pozniak,2 Horacio Mingrone,3 Carlos Brites,4 Jaime Federico Andrade-Villanueva,5 Jan Fourie,6 Moti Ramgopal,7 Debbie Hagins,8 Jose Madruga,9 Tamara Newman,10 John Lombaard,11 David Dorey,12 Mark Underwood,13 Sandy Griffith,13 Sherene Min,13 on behalf of the extended SAILING study team 1Fundacion Huesped, Buenos Aires, Argentina; 2Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; 3Fundacion IDEAA, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina; 4Complexo Hospitalar Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil; 5Hospital Civil de Guadalajara "Fray Antonio Alcalde," CUCS, Universidad de Guadalajara, Guadalajara, Mexico; 6Fourie Medical Centre, Dundee, South Africa; 7Midway Immunology and Research Center, Fort Pierce, FL, USA; 8Chatham CARE Center, Savannah, GA, USA; 9Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; 10Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil; 11JOSHA Research, Bloemfontein, South Africa; 12-13GlaxoSmithKline, 12Mississauga, ON, Canada; 13Research Triangle Park, NC, USA